Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Nabs $7.5 Million in Debt-Financing

NEW YORK, July 10 - Paradigm Genetics will pocket $7.5 million as part of a  debt-financing deal with Silicon Valley Bank of Santa Clara, Calif., Paradigm said today.

 

Paradigm said the financing includes a $5 million, four-year secured-term loan and a $2.5 million revolving line of credit. The firm added that the loan is at a "significantly lower [interest] rate" than its existing loan.

 

Paradigm, based in Research Triangle Park, NC, will use around $3 million of the term loan to pay off its current equipment financing loan with Transamerica Technology Finance, which was to mature in June 2004. The company said it will use the balance of the cash for "general corporate purposes."

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.